<DOC>
	<DOCNO>NCT00002971</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness O ( 6 ) -benzylguanine give surgery patient malignant glioma .</brief_summary>
	<brief_title>O ( 6 ) -Benzylguanine Treating Patients With Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine dose O6-benzylguanine ( O6-BG ) produce total depletion tumor O6-alkylguanine-DNA alkyltransferase ( AGT ) level 90 % patient cerebral anaplastic astrocytoma glioblastoma multiforme . - Determine qualitative quantitative toxicity O6-BG patient population . OUTLINE : This dose escalation study . Part I : The first cohort 10 patient receive O6-benzylguanine ( O6-BG ) IV 1 hour dose level 1 begin 6 hour prior surgery . If least 3 10 patient first cohort detectable level O6-alkylguanine-DNA alkyltransferase ( AGT ) , second cohort 10 patient receive O6-BG dose level 2 . Dose escalation continue least 8 10 patient undetectable AGT activity . At point , 4 additional patient accrue . If least 11 14 patient dose level undetectable level AGT , dose level constitutes biologic modulatory dose O6-BG . If less 11 14 patient undetectable level AGT , 10 additional patient treat high dose . If time 3 patient dose level detectable AGT activity , accrual stop dose level patient treat next high dose level . ( Part I close accrual effective 7/10/2000 ) Part II : An additional cohort 14 patient receive O6-BG dose level 5 begin 18 hour prior surgery . PROJECTED ACCRUAL : Part I study close accrual effective 7/10/2000 . A total 14 patient accrue part II study rate 3 patient per month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Must undergo diagnostic/therapeutic craniotomy biopsy/resection recurrent newly diagnose ( presume ) cerebral anaplastic astrocytoma glioblastoma multiforme Patients undergoing stereotactic biopsy partial resection eligible PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 OR Karnofsky 60100 % Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,800/mm3 Platelet count least 125,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin le 1.5 mg/dL SGOT le 2 time upper limit normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 70 mL/min Cardiovascular : No cardiovascular illness adequately control appropriate therapy would increase risk , e.g . : Severe cardiac disease uncontrolled arrhythmias conduction defect Major problem edema ( e.g. , residual leg swell deep venous thrombosis ) Recent coronary artery disease Poorly control hypertension ( systolic pressure great 180 mm Hg , diastolic pressure great 110 mm Hg ) Other : No medical illness adequately control appropriate therapy would increase risk , e.g . : Major problem edema ( e.g. , Cushing 's syndrome ) Major psychiatric illness No malignancy require active therapy Not pregnant nursing Fertile patient must u effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Must fail receive prior treatment nitrosourea , procarbazine , temozolomide No prior O6benzylguanine At least 4 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : At least 6 week since prior radiotherapy No prior radiotherapy great 1020 % bone marrow Other : No concurrent therapy malignancy At least 2 week since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>